Prof. Dr. med. Roland Schmieder

Medizinische Fakultät Professur für Innere Medizin (Nephrologie)

Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications (2021) Mahfoud F, Weber M, Schmieder R, Lobo MD, Blankestijn PJ, Persu A, Fischell TA, et al. Journal article Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke (2021) Boehm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, et al. Journal article Criteria of the German Cardiac Society (DGK), the German Hypertension League DHL (R)/German Society for Hypertension and Prevention and the German Society for Nephrology (DGfN) on certification of renal denervation centers (RDZ)-Update (2021) Mahfoud F, Galle J, Schunkert H, Schmieder R, Rump LC, Limbourg FP, Van Der Giet M, et al. Journal article Responsiveness of afferent renal nerve units in renovascular hypertension in rats (2021) Rodionova K, Hilgers KF, Rafii-Tabrizi S, Doellner J, Cordasic N, Linz P, Karl A, et al. Journal article Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial (2021) Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, et al. Journal article Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial (2021) Salib M, Girerd S, Girerd N, Marz W, Scharnagl H, Massy ZA, Leroy C, et al. Journal article Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation (2021) Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder R, Tsioufis K, Pocock S, et al. Journal article AT II Receptor Blockade and Renal Denervation: Different Interventions with Comparable Renal Effects? (2021) Rodionova K, Hindermann M, Hilgers KF, Ott C, Schmieder R, Schiffer M, Amann KU, et al. Journal article, Original article THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Bosch A, Jung S, Linz P, Kannenkeril D, Nagel AM, Ott C, et al. Conference contribution